Diacylglycerols as biomarkers of sustained immune activation in Proteinopathies associated with dementia

Paul L. Wood, John E. Cebak, Randall L. Woltjer

Research output: Contribution to journalReview article

Abstract

Cognitive decline is a devastating clinical condition, heavily correlated with age progression. In the cases of Alzheimer's disease, Parkinson's disease, and Lewy body disease, the common neuropathologies are proteinopathies and neuroinflammation. Herein, we review current lipidomics findings and conclude that brain and circulating diacylglycerols represent biomarkers of this ongoing sustained immune response, presumably involving microglia. We further hypothesize that a logical next step will be to evaluate biomarkers of immune activation in a cohort of patients with Mild Cognitive Impairment (MCI) and subsequently attempt to provide therapeutic intervention with anti-inflammatory therapy in MCI patients with immune activation. Although this is an urgent and theoretically safe therapeutic trial, it will likely necessitate government support.

LanguageEnglish (US)
Pages107-110
Number of pages4
JournalClinica Chimica Acta
Volume476
DOIs
StatePublished - Jan 1 2018

Fingerprint

Diglycerides
Biomarkers
Dementia
Chemical activation
Lewy Body Disease
Microglia
Parkinson Disease
Brain
Alzheimer Disease
Anti-Inflammatory Agents
Therapeutics
Cognitive Dysfunction

Keywords

  • Cognitive dysfunction
  • Diacylglycerols
  • Immune activation
  • Neuroinflammation
  • Proteinopathies

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Diacylglycerols as biomarkers of sustained immune activation in Proteinopathies associated with dementia. / Wood, Paul L.; Cebak, John E.; Woltjer, Randall L.

In: Clinica Chimica Acta, Vol. 476, 01.01.2018, p. 107-110.

Research output: Contribution to journalReview article

@article{3250c91f14564b169bcb2435212c4e92,
title = "Diacylglycerols as biomarkers of sustained immune activation in Proteinopathies associated with dementia",
abstract = "Cognitive decline is a devastating clinical condition, heavily correlated with age progression. In the cases of Alzheimer's disease, Parkinson's disease, and Lewy body disease, the common neuropathologies are proteinopathies and neuroinflammation. Herein, we review current lipidomics findings and conclude that brain and circulating diacylglycerols represent biomarkers of this ongoing sustained immune response, presumably involving microglia. We further hypothesize that a logical next step will be to evaluate biomarkers of immune activation in a cohort of patients with Mild Cognitive Impairment (MCI) and subsequently attempt to provide therapeutic intervention with anti-inflammatory therapy in MCI patients with immune activation. Although this is an urgent and theoretically safe therapeutic trial, it will likely necessitate government support.",
keywords = "Cognitive dysfunction, Diacylglycerols, Immune activation, Neuroinflammation, Proteinopathies",
author = "Wood, {Paul L.} and Cebak, {John E.} and Woltjer, {Randall L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cca.2017.11.009",
language = "English (US)",
volume = "476",
pages = "107--110",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Diacylglycerols as biomarkers of sustained immune activation in Proteinopathies associated with dementia

AU - Wood,Paul L.

AU - Cebak,John E.

AU - Woltjer,Randall L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cognitive decline is a devastating clinical condition, heavily correlated with age progression. In the cases of Alzheimer's disease, Parkinson's disease, and Lewy body disease, the common neuropathologies are proteinopathies and neuroinflammation. Herein, we review current lipidomics findings and conclude that brain and circulating diacylglycerols represent biomarkers of this ongoing sustained immune response, presumably involving microglia. We further hypothesize that a logical next step will be to evaluate biomarkers of immune activation in a cohort of patients with Mild Cognitive Impairment (MCI) and subsequently attempt to provide therapeutic intervention with anti-inflammatory therapy in MCI patients with immune activation. Although this is an urgent and theoretically safe therapeutic trial, it will likely necessitate government support.

AB - Cognitive decline is a devastating clinical condition, heavily correlated with age progression. In the cases of Alzheimer's disease, Parkinson's disease, and Lewy body disease, the common neuropathologies are proteinopathies and neuroinflammation. Herein, we review current lipidomics findings and conclude that brain and circulating diacylglycerols represent biomarkers of this ongoing sustained immune response, presumably involving microglia. We further hypothesize that a logical next step will be to evaluate biomarkers of immune activation in a cohort of patients with Mild Cognitive Impairment (MCI) and subsequently attempt to provide therapeutic intervention with anti-inflammatory therapy in MCI patients with immune activation. Although this is an urgent and theoretically safe therapeutic trial, it will likely necessitate government support.

KW - Cognitive dysfunction

KW - Diacylglycerols

KW - Immune activation

KW - Neuroinflammation

KW - Proteinopathies

UR - http://www.scopus.com/inward/record.url?scp=85034863400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034863400&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2017.11.009

DO - 10.1016/j.cca.2017.11.009

M3 - Review article

VL - 476

SP - 107

EP - 110

JO - Clinica Chimica Acta

T2 - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -